Pfizer Withdraws Oxbryta, But Overall Market Impact May Be Limited
EU Regulators Recommend Suspending Approval
The withdrawal amid concerns about the risk-benefit ratio reduces treatment options for sickle cell disease, but it is not expected to have much effect on the SCD market, including the gene therapies.
